AptaBio Therapeutics Inc (293780) — Strategic Asset Allocation Index
AptaBio Therapeutics Inc (293780) has a Strategic Asset Allocation Index of 11.7% as of March 2025. Strategic assets (PP&E of ₩6.07 Billion plus long-term investments of ₩-) total ₩6.07 Billion, measured against net assets of ₩51.73 Billion. A higher index reflects capital-intensive or investment-heavy strategies where strategic assets dominate the equity base. See AptaBio Therapeutics Inc (293780) net asset quality to measure how much of total assets are equity-financed.
SAAI
Strategic Assets
PP&E
Net Assets
AptaBio Therapeutics Inc Strategic Asset Allocation Index (2018–2022)
This chart shows how AptaBio Therapeutics Inc's Strategic Asset Allocation Index has evolved across 5 annual periods from 2018 to 2022. As of March 2025, the index stands at 11.7%, representing strategic assets of ₩6.07 Billion against net assets of ₩51.73 Billion KRW. For live market cap and overall valuation, see 293780 company net worth.
Annual Strategic Asset Allocation Index for AptaBio Therapeutics Inc (2018–2022)
The table below presents the year-by-year Strategic Asset Allocation Index for AptaBio Therapeutics Inc from 2018 to 2022, covering 5 annual filings. Each row shows PP&E, long-term investments, strategic assets combined, net assets, the index percentage, and the change in percentage points compared to the prior year. See AptaBio Therapeutics Inc shareholders equity for net asset value and shareholders' equity analysis.
| Year | SAAI | Strategic Assets (KRW) | PP&E | LT Investments | Net Assets | Change (pp) |
|---|---|---|---|---|---|---|
| 2022 | 11.2% | ₩5.85 Billion | ₩5.85 Billion | ₩- | ₩52.37 Billion | ▲ +3.3 pp |
| 2021 | 7.8% | ₩4.82 Billion | ₩4.82 Billion | ₩- | ₩61.67 Billion | ▲ +1.0 pp |
| 2020 | 6.8% | ₩4.89 Billion | ₩4.89 Billion | ₩- | ₩72.04 Billion | ▲ +1.4 pp |
| 2019 | 5.4% | ₩4.03 Billion | ₩4.03 Billion | ₩- | ₩75.16 Billion | ▲ +3.8 pp |
| 2018 | 1.6% | ₩287.09 Million | ₩287.09 Million | ₩- | ₩18.31 Billion | — |